Teknova Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $12.7 million, up 22% year over year
- ➤2026 revenue guidance raised to $46-48 million
- ➤October equity offering generated $46.0 million gross proceeds
- ➤Q3 net loss narrowed to $3.5 million, or $0.06 per share
- ➤Clinical Solutions revenue $3.2 million, up 86% year over year
Expert Statements
Stephen Gunstream, President and Chief Executive Officer of Teknova
“We posted record revenue for the second consecutive quarter”
Stephen Gunstream, President and Chief Executive Officer of Teknova
“Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers.”
Stephen Gunstream, President and Chief Executive Officer of Teknova
“Notably, there was an increase in purchases of our custom products by small and mid-sized biotech customers and their associated contract manufacturers, which we believe is an early indication of biotech funding improvements over the past four quarters.”
Matt Lowell, Chief Financial Officer of Teknova
“We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by 22% revenue growth and a significant improvement in Adjusted EBITDA and Free Cash Outflow.”
Matt Lowell, Chief Financial Officer of Teknova
“We are therefore raising our 2026 revenue guidance to $46-48 million and maintaining our expectations for full-year Free Cash Outflow of less than $8 million”
Matt Lowell, Chief Financial Officer of Teknova
“We are also pleased with the balance sheet flexibility we achieved with our $46 million equity capital raise in October and that we were able to welcome a significant number of new investors to Teknova’s shareholder base through the offering”
Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year Company raises 2026 revenue guidance to $46-48 million Strengthened balance sheet with $46 million public equity offering completed in October 2026
HOLLISTER, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.